B. Balana, J. Schoellerman, B. Lord
Apr 1, 2020
The FASEB Journal
Blockade of GluN2B (NR2B)‐containing NMDA receptors has been proposed as a therapy for a number of neurological and psychiatric diseases including mood disorders. A number of GluN2B antagonists have been identified and developed over the last three decades. These compounds, however, have significant limitations in regard to their selectivity or drug‐like properties (e.g. oral bioavailability).